Chief investigator ABCD REVISE-Diabesity and End-OSA Studies with Endobarrier

Clinical lead, ABCD worldwide EndoBarrier registry

Clinical lead, ABCD audits of new diabetes therapies and devices

Author: An Aid to the MRCP Short Cases

An Aid to the MRCP PACES

Consultant Diabetologist

City Hospital

UK

Co-opted Website Co-ordinator & Clinical Lead, Nationwide Audits of New Diabetes Therapies

Bob Ryder trained in South Wales and Sheffield. He has worked as a Consultant Physician/Diabetologist/Endocrinologist, City Hospital, Birmingham since 1991. Over the years special interests have included diabetic retinopathy screening; diabetic hypoglycaemia unawareness; diabetic autonomic neuropathy; diabetic impotence; clinical use of IT; treating to target; relative risks and benefits of pioglitazone He leads the ABCD nationwide audits of new therapies and devices – current audits include SGLT2i, FreeStyle Libre, semaglutide, COVID 19 and diabetes, testosterone, closed-loop systems, oral semaglutide and Omnipod. He is chief investigator of two ABCD Endobarrier studies. Beyond diabetes he is best known as principal author of best-selling "An Aid to the MRCP Short Cases", the 4th-edition of which is the three volume “An Aid to the MRCP PACES”.